Today I will be live-blogging the FDA?s??Cardiovascular and Renal Drugs Advisory Committee meeting to consider the??supplemental new drug application (sNDA) for??rivaroxaban (Xarelto, ) for use in patients with acute coronary syndrome (ACS) already taking dual antiplatelet therapy.??Here is a link to the FDA briefing documents.??And if you want to follow along from home you can ...
Read More... [Source: - Posted by FreeAutoBlogger]